ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Show more

Zernikedreef 9, Leiden, 2333 CK, Netherlands

https://www.proqr.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

180.2M

52 Wk Range

$1.07 - $3.10

Previous Close

$1.71

Open

$1.70

Volume

241,182

Day Range

$1.63 - $1.74

Enterprise Value

90.64M

Cash

92.41M

Avg Qtr Burn

-13.36M

Insider Ownership

18.10%

Institutional Own.

50.80%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AX-0810 Details NTCP for Cholestatic diseases	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AX-2911 (RNA Editing Oligonucleotide) Details Metabolic-Associated Steatohepatitis (PNPLA3 I148M)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AX-2402 (RNA Editing Oligonucleotide) Details Rett Syndrome (MECP2 R270X)	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QR-1123 (RNase H mediated cleavage) Details Mediated retinitis pigmentosa, Rho mediated retinitis pigmentosa	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ultevursen (QR-421a) (Exon 13) Details Mediated retinitis pigmentosa, Usher syndrome, Heart disease, Heart failure	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sepofarsen (QR-110) (CEP290 gene) Details Leber congenital amaurosis, Eye disease , Genetic disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
QR-504a Details Genetic disorder, Eye disease , Leber congenital amaurosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.